Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $424.94
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 | Guggenheim | maintain | Neutral | Neutral |
| Oct 12, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Oct 12, 26 | BMO Capital | maintain | Market Perform | Market Perform |
| Oct 9, 26 | UBS | maintain | Buy | Buy |
| Oct 8, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 8, 26 | Cantor Fitzgerald | maintain | Neutral | Neutral |
| Oct 7, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Oct 7, 26 | Truist Securities | maintain | Hold | Hold |
| Sep 29, 26 | Scotiabank | maintain | Sector Outperform | Sector Outperform |
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | Dittrich Thomas J.W. | officer: EVP & CFO | 0 | — | |
FY2025 · 10-K disclosure
| 4 | Aug 10, 2026 | 2026-08-10 20:22:32 | View |
| 4 | Aug 10, 2026 | 2026-08-10 20:20:01 | View |
| 4 | Aug 7, 2026 | 2026-08-07 18:47:09 | View |
| 4 | Aug 7, 2026 | 2026-08-07 18:45:54 | View |
| 10-Q | Aug 5, 2026 | 2026-08-04 18:29:07 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 16:03:16 | View |
Proxy statement (DEF 14A) disclosures
| Aug 7, 27 |
| Dittrich Thomas J.W. |
| officer: EVP & CFO |
| 17,201 @ $410.95 |
| $7.07M |
| Aug 13, 26 | Khosla Rachna | officer: SVP, Business Development | M-Exempt | 1,252 @ $162.60 | $203.6K |
| Aug 13, 26 | Khosla Rachna | officer: SVP, Business Development | S-Sale | 1,252 @ $416.43 | $521.4K |
| Aug 11, 26 | Khosla Rachna | officer: SVP, Business Development | S-Sale | 2,000 @ $412.57 | $825.1K |
| Aug 13, 26 | Khosla Rachna | officer: SVP, Business Development | M-Exempt | 1,252 @ $162.60 | $203.6K |
| Aug 7, 26 | Busch Matthew C. | officer: VP, Finance & CAO | A-Award | 730 | — |
| Aug 7, 26 | Ishrak Omar | director | A-Award | 85 | — |
Stock news · updated daily
When a drugmaker's top product loses patent protection, the dividend usually takes the hit.
Treasury yields have turned dividend investing into a minefield, but five mega-caps have quietly raised their payouts through every rate spike, recession, and patent cliff of the past four decades.
Amgen (AMGN) closed at $447.28 in the latest trading session, marking a +2.04% move from the prior day.
Amgen maintains a diverse portfolio focused on oncology, rare diseases, and inflammation while providing steady cash flow generation. Eli Lilly & Co. continues to see explosive growth driven by its dominant position in the cardiometabolic and incretin drug markets.
Both of these ETFs look the part, but only one is truly the better buy for investors.
Amgen is demonstrating strong top-line growth driven by a diverse portfolio in oncology and rare diseases. Bristol Myers Squibb remains a heavy producer of free cash flow while offering a significantly lower valuation.
THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m.
A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY | LLY Price Prediction) stock ahead of the rest of the drug group. Eli Lilly stock is up 4% to $1,295.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 5.62 | 6.29 | Beat 11.9% | $10.05B |
| Apr 30, 2026 | 4.77 | 5.15 | Beat 8.0% | $8.62B |
| Feb 3, 2026 | 4.73 | 5.29 | Beat 11.8% | $9.87B |
| Nov 4, 2025 | 5.02 | 5.64 | Beat 12.4% | $9.56B |
| Aug 5, 2025 | 5.28 | 6.02 | Beat 14.0% | $9.17B |
| May 1, 2025 | 4.27 | 4.90 | Beat 14.8% | $8.15B |
TTM vs. 5-year historical average (annual ratios)
| Metric | AMGN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 26.2x | 24.7x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 18.4x | EPS est. 23.04 | Discount |
| Price / Book | 19.6x | 25.4x | Discount |
| Price / Sales | 6.0x | 5.0x | Elevated |
| EV / EBITDA | 15.5x | 13.8x | In line |
| Return on equity | 89.3% | — | Top tier |
| Gross margin | 72.7% | 70.7% | In line |
| Debt / Equity | 4.90 | 8.50 | Levered |
| Piotroski / Altman Z | 8/9 | Z 2.31 | Grey zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-19
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 56.97 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 75.36 | Oscillator | Neutral |
| Williams %R (14) | -36.77 | Oscillator | Neutral |
| MACD (12, 26, 9) | 5.50 (Hist 2.34) | Oscillator | Strong Buy |
| Average Directional Index (14) | 23.53 (+DI 33.0 / -DI 19.9) | Trend | Buy |
| EMA 20 | 415.83 | MA | Buy |
| SMA 20 | 414.98 | MA | Buy |
| EMA 50 | 407.69 | MA | Strong Buy |
| SMA 50 | 415.29 | MA | Buy |
| SMA 200 | 369.39 | MA | Strong Buy |